Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-130 in Early Manifest Huntington Disease (EU Phase Ib/II)
2024-511766-37-00Phase 2Authorised
- Sponsor
- uniQure
- Start
- Jul 2024
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ifezuntirgene inilparvovec in Huntington disease (HD) (2 arms), sponsored by uniQure. Primary endpoints: Type and incidence of adverse events, Change from baseline in vital signs, ECG parameters, physical and neurological examinations and 7 more. Planned start Jul 2024; status: authorised.
02
Drugs
ifezuntirgene inilparvovec
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2024-511766-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511766-37-00.